- Home
- AGEN vs CHMI Comparison
AGEN vs CHMI Comparison
Compare AGEN & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- CHMI
- Stock Information
- Founded
- AGEN 1994
- CHMI 2012
- Country
- AGEN United States
- CHMI United States
- Employees
- AGEN N/A
- CHMI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CHMI Real Estate Investment Trusts
- Sector
- AGEN Health Care
- CHMI Real Estate
- Exchange
- AGEN Nasdaq
- CHMI Nasdaq
- Market Cap
- AGEN 96.2M
- CHMI 92.0M
- IPO Year
- AGEN 2000
- CHMI 2013
- Fundamental
- Price
- AGEN $3.83
- CHMI $3.00
- Analyst Decision
- AGEN Buy
- CHMI Buy
- Analyst Count
- AGEN 3
- CHMI 2
- Target Price
- AGEN $10.50
- CHMI $5.00
- AVG Volume (30 Days)
- AGEN 399.9K
- CHMI 464.1K
- Earning Date
- AGEN 03-13-2025
- CHMI 03-06-2025
- Dividend Yield
- AGEN N/A
- CHMI 20.16%
- EPS Growth
- AGEN N/A
- CHMI N/A
- EPS
- AGEN N/A
- CHMI N/A
- Revenue
- AGEN $160,427,000.00
- CHMI N/A
- Revenue This Year
- AGEN N/A
- CHMI N/A
- Revenue Next Year
- AGEN $36.13
- CHMI $27.78
- P/E Ratio
- AGEN N/A
- CHMI N/A
- Revenue Growth
- AGEN 59.00
- CHMI N/A
- 52 Week Low
- AGEN $2.50
- CHMI $2.50
- 52 Week High
- AGEN $19.69
- CHMI $3.99
- Technical
- Relative Strength Index (RSI)
- AGEN 65.58
- CHMI 65.37
- Support Level
- AGEN $3.08
- CHMI $2.67
- Resistance Level
- AGEN $3.29
- CHMI $2.83
- Average True Range (ATR)
- AGEN 0.27
- CHMI 0.10
- MACD
- AGEN 0.08
- CHMI 0.04
- Stochastic Oscillator
- AGEN 94.84
- CHMI 94.51
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.